These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23787730)

  • 1. A practical strategy of monitoring minimal residue disease and intervention for central nervous system relapse of childhood acute lymphoblastic leukemia: a single Chinese center's experience.
    Liang Y; Ca Q; Zhai ZM; Wang NL
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):388-93. PubMed ID: 23787730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia.
    Mahmoud HH; Rivera GK; Hancock ML; Krance RA; Kun LE; Behm FG; Ribeiro RC; Sandlund JT; Crist WM; Pui CH
    N Engl J Med; 1993 Jul; 329(5):314-9. PubMed ID: 8321259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of performing the initial lumbar puncture on day 8 in remission induction therapy for childhood acute lymphoblastic leukemia: TCCSG L99-15 study.
    Hasegawa D; Manabe A; Ohara A; Kikuchi A; Koh K; Kiyokawa N; Fukushima T; Ishida Y; Saito T; Hanada R; Tsuchida M;
    Pediatr Blood Cancer; 2012 Jan; 58(1):23-30. PubMed ID: 21254378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
    Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
    Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
    Coustan-Smith E; Gajjar A; Hijiya N; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Andreansky M; Hancock ML; Pui CH; Campana D
    Leukemia; 2004 Mar; 18(3):499-504. PubMed ID: 14981525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multicenter evaluation of minimal residual disease monitoring in early induction therapy for treatment of childhood acute lymphoblastic leukemia].
    Wu XJ; Liao N; Mai HR; Li XY; Wan WQ; Yang LH; Huang LB; Luo XQ; Tian C; Chen QW; Long XJ; He YY; Wang Y; Li ZG; Xu HG
    Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):337-344. PubMed ID: 38527504
    [No Abstract]   [Full Text] [Related]  

  • 7. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
    Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A
    Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity as the initial manifestation of central nervous system relapse of acute lymphoblastic leukemia: case report and literature review.
    Zhang LD; Li YH; Ke ZY; Huang LB; Luo XQ
    J Cancer Res Ther; 2012; 8(1):151-3. PubMed ID: 22531539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881.
    Sirvent N; Suciu S; Rialland X; Millot F; Benoit Y; Plantaz D; Ferster A; Robert A; Lutz P; Nelken B; Plouvier E; Norton L; Bertrand Y; Otten J
    Eur J Cancer; 2011 Jan; 47(2):239-47. PubMed ID: 21095115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
    Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
    Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
    Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
    Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia.
    Xu XJ; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Xu WQ
    Leuk Res; 2012 Aug; 36(8):1022-7. PubMed ID: 22483330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
    Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of sequential monitoring minimal residual disease in childhood B-cell acute lymphoblastic leukemia].
    Wang L; Jiang H; Li H; Shao JB; Lu ZH; Yang JW; Yang WQ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jun; 32(6):400-3. PubMed ID: 21781499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
    Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
    Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
    Chen JS; Hsiao CC; Sheen JM; Cheng CN
    Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
    Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
    Ryan J; Quinn F; Meunier A; Boublikova L; Crampe M; Tewari P; O'Marcaigh A; Stallings R; Neat M; O'Meara A; Breatnach F; McCann S; Browne P; Smith O; Lawler M
    Br J Haematol; 2009 Jan; 144(1):107-15. PubMed ID: 19016726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.